The Food and Drug Administration has approved a new test to help physicians diagnose a group of rare cell disorders. The test, or assay, was developed by an expert at Virginia Commonwealth University in the field of mast cells. Lawrence Schwartz, M.D., Ph.D., chair of the Division of...
Precision Therapeutics announced that The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of...
Precision Therapeutics announced that The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of...
Predictive Biosciences today announced that Company scientists will be presenting a novel multi-analyte approach to the development of a non-invasive, urine-biomarker based diagnostic assay during the 10th Annual Meeting of the Society of Urologic Oncology (SUO). The research was done under...